Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc. (RETA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
reta · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Reata Pharmaceuticals, Inc.You RETA | $6.6B | N/A | — | -$8.59 |
 Abcam plc ABCM | $5.5B | N/A | — | -$0.04 |
 Alpine Immune Sciences, Inc. ALPN | $4.5B | N/A | — | -$0.64 |
 Blueprint Medicines Corporation BPMC | $8.4B | N/A | — | -$1.07 |
 Cerevel Therapeutics Holdings, Inc. CERE | $8.2B | N/A | — | -$2.67 |
 ImmunoGen, Inc. IMGN | $8.7B | N/A | — | -$0.88 |
 IVERIC bio, Inc. ISEE | $5.5B | N/A | — | -$1.45 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Reata Pharmaceuticals, Inc. (RETA) measures how much investors pay for each dollar of the company's trailing earnings. RETA's current PE ratio of N/A is calculated by dividing its stock price of $172.36 by its TTM earnings per share of -$8.59.
Frequently asked questions
RETA pe ratio · 6 questionsRETA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $172.36 and TTM EPS of -$8.59. Data sourced from Financial Modeling Prep via RETA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Reata Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09